PREFEREnce-based randomized evaluation of treatment modalities in low or early intermediate-risk prostate cancer - Abstract

The clinical trial PREFERE aims to recruit 7600 patients with "early intermediate" prostate cancer.

The goal is to confirm noninferiority of cancer-specific survival after external-beam radiotherapy, permanent seed implantation, or active surveillance compared with radical prostatectomy.

Written by:
Wiegel T, Stöckle M, Bartkowiak D.   Are you the author?
Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany; Department of Urology, University Hospital Homburg/Saar, Homburg, Germany.  

Reference: Eur Urol. 2014 Sep 27. pii: S0302-2838(14)00911-7.
doi: 10.1016/j.eururo.2014.09.016

PubMed Abstract
PMID: 25269383 Prostate Cancer Section